The Latest Breaking News from AbbVie

The Federal Reserve cut rates again at its December meeting, and lower borrowing costs could boost these large-cap stocks.

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Although Abbvie stock has been lagging behind the broader market over the past year, Wall Street analysts are still moderately bullish about its outlook.

This article covers three buy-rated companies that've increased their dividends for 50+ consecutive years.

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

June S&P 500 E-Mini futures (ESM24) are up +0.63%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.86% this morning as upbeat quarterly results from tech titans Alphabet and Microsoft boosted sentiment, while investors geared up for the release of the Fed’s preferred inflation gauge.

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).